Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS‐CoV‐2 convalescent plasma donors
Background Several studies have described associations between ABO blood group and SARS‐CoV‐2 infection severity in hospitalized patients where group A individuals are over‐represented and group O individuals may have a lower infection rate. In convalescent individuals, group B blood donors have hig...
Saved in:
Published in | Transfusion Vol. 62; no. 2; pp. 292 - 297 |
---|---|
Main Authors | , , , |
Format | Journal Article Web Resource |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.02.2022
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
Several studies have described associations between ABO blood group and SARS‐CoV‐2 infection severity in hospitalized patients where group A individuals are over‐represented and group O individuals may have a lower infection rate. In convalescent individuals, group B blood donors have higher neutralizing SARS‐CoV‐2 antibody titers. We analyzed whether there was any correlation of ABO Rh(D) blood group with SARS‐CoV‐2 infection and with neutralizing antibodies in Australian convalescent plasma (CP) donors.
Study Design and Methods
ABO Rh(D) distribution and demographics of CP donors (n = 765) were compared with the total blood donor panel (n = 488,028), plasmapheresis donors (n = 203,176) and whole blood donors (n = 282,437) from 2020. The presence of neutralizing antibodies in CP donors was measured using the Vero E6 cell microneutralization assay.
Results
The distribution of ABO group in CP donors compared to the total donor panel was not significantly different (p = .177). There were significantly more group AB donors in the plasmapheresis subset (p = .005) and group O individuals were over‐represented in the whole blood donor subset (p < .0001). There was no significant difference in neutralizing antibody levels among CP donors with differing ABO blood groups (p = .872).
Conclusion
ABO Rh(D) blood group distribution was not found to be significantly different between convalescent plasma donors and general blood donors in our large sample group. Inherent blood donor selection biases associated with clinical demand accounted for some differences within CP donors. The levels of SARS‐CoV‐2 neutralizing antibodies were also not significantly associated with ABO Rh(D) group. |
---|---|
AbstractList | BACKGROUNDSeveral studies have described associations between ABO blood group and SARS-CoV-2 infection severity in hospitalized patients where group A individuals are over-represented and group O individuals may have a lower infection rate. In convalescent individuals, group B blood donors have higher neutralizing SARS-CoV-2 antibody titers. We analyzed whether there was any correlation of ABO Rh(D) blood group with SARS-CoV-2 infection and with neutralizing antibodies in Australian convalescent plasma (CP) donors. STUDY DESIGN AND METHODSABO Rh(D) distribution and demographics of CP donors (n = 765) were compared with the total blood donor panel (n = 488,028), plasmapheresis donors (n = 203,176) and whole blood donors (n = 282,437) from 2020. The presence of neutralizing antibodies in CP donors was measured using the Vero E6 cell microneutralization assay. RESULTSThe distribution of ABO group in CP donors compared to the total donor panel was not significantly different (p = .177). There were significantly more group AB donors in the plasmapheresis subset (p = .005) and group O individuals were over-represented in the whole blood donor subset (p < .0001). There was no significant difference in neutralizing antibody levels among CP donors with differing ABO blood groups (p = .872). CONCLUSIONABO Rh(D) blood group distribution was not found to be significantly different between convalescent plasma donors and general blood donors in our large sample group. Inherent blood donor selection biases associated with clinical demand accounted for some differences within CP donors. The levels of SARS-CoV-2 neutralizing antibodies were also not significantly associated with ABO Rh(D) group. Background Several studies have described associations between ABO blood group and SARS‐CoV‐2 infection severity in hospitalized patients where group A individuals are over‐represented and group O individuals may have a lower infection rate. In convalescent individuals, group B blood donors have higher neutralizing SARS‐CoV‐2 antibody titers. We analyzed whether there was any correlation of ABO Rh(D) blood group with SARS‐CoV‐2 infection and with neutralizing antibodies in Australian convalescent plasma (CP) donors. Study Design and Methods ABO Rh(D) distribution and demographics of CP donors (n = 765) were compared with the total blood donor panel (n = 488,028), plasmapheresis donors (n = 203,176) and whole blood donors (n = 282,437) from 2020. The presence of neutralizing antibodies in CP donors was measured using the Vero E6 cell microneutralization assay. Results The distribution of ABO group in CP donors compared to the total donor panel was not significantly different (p = .177). There were significantly more group AB donors in the plasmapheresis subset (p = .005) and group O individuals were over‐represented in the whole blood donor subset (p < .0001). There was no significant difference in neutralizing antibody levels among CP donors with differing ABO blood groups (p = .872). Conclusion ABO Rh(D) blood group distribution was not found to be significantly different between convalescent plasma donors and general blood donors in our large sample group. Inherent blood donor selection biases associated with clinical demand accounted for some differences within CP donors. The levels of SARS‐CoV‐2 neutralizing antibodies were also not significantly associated with ABO Rh(D) group. Several studies have described associations between ABO blood group and SARS-CoV-2 infection severity in hospitalized patients where group A individuals are over-represented and group O individuals may have a lower infection rate. In convalescent individuals, group B blood donors have higher neutralizing SARS-CoV-2 antibody titers. We analyzed whether there was any correlation of ABO Rh(D) blood group with SARS-CoV-2 infection and with neutralizing antibodies in Australian convalescent plasma (CP) donors. ABO Rh(D) distribution and demographics of CP donors (n = 765) were compared with the total blood donor panel (n = 488,028), plasmapheresis donors (n = 203,176) and whole blood donors (n = 282,437) from 2020. The presence of neutralizing antibodies in CP donors was measured using the Vero E6 cell microneutralization assay. The distribution of ABO group in CP donors compared to the total donor panel was not significantly different (p = .177). There were significantly more group AB donors in the plasmapheresis subset (p = .005) and group O individuals were over-represented in the whole blood donor subset (p < .0001). There was no significant difference in neutralizing antibody levels among CP donors with differing ABO blood groups (p = .872). ABO Rh(D) blood group distribution was not found to be significantly different between convalescent plasma donors and general blood donors in our large sample group. Inherent blood donor selection biases associated with clinical demand accounted for some differences within CP donors. The levels of SARS-CoV-2 neutralizing antibodies were also not significantly associated with ABO Rh(D) group. Background Several studies have described associations between ABO blood group and SARS-CoV-2 infection severity in hospitalized patients where group A individuals are over-represented and group O individuals may have a lower infection rate. In convalescent individuals, group B blood donors have higher neutralizing SARS-CoV-2 antibody titers. We analyzed whether there was any correlation of ABO Rh(D) blood group with SARS-CoV-2 infection and with neutralizing antibodies in Australian convalescent plasma (CP) donors. Study Design and Methods ABO Rh(D) distribution and demographics of CP donors (n = 765) were compared with the total blood donor panel (n = 488,028), plasmapheresis donors (n = 203,176) and whole blood donors (n = 282,437) from 2020. The presence of neutralizing antibodies in CP donors was measured using the Vero E6 cell microneutralization assay. Results The distribution of ABO group in CP donors compared to the total donor panel was not significantly different (p = .177). There were significantly more group AB donors in the plasmapheresis subset (p = .005) and group O individuals were over-represented in the whole blood donor subset (p < .0001). There was no significant difference in neutralizing antibody levels among CP donors with differing ABO blood groups (p = .872). Conclusion ABO Rh(D) blood group distribution was not found to be significantly different between convalescent plasma donors and general blood donors in our large sample group. Inherent blood donor selection biases associated with clinical demand accounted for some differences within CP donors. The levels of SARS-CoV-2 neutralizing antibodies were also not significantly associated with ABO Rh(D) group. |
Author | Hirani, Rena Gosbell, Iain B. Hoad, Veronica Irving, David O. |
Author_xml | – sequence: 1 givenname: Rena orcidid: 0000-0003-0371-9515 surname: Hirani fullname: Hirani, Rena email: rhirani@redcrossblood.org.au organization: Macquarie University – sequence: 2 givenname: Veronica orcidid: 0000-0002-7827-3661 surname: Hoad fullname: Hoad, Veronica organization: Australian Red Cross Lifeblood – sequence: 3 givenname: Iain B. surname: Gosbell fullname: Gosbell, Iain B. organization: Western Sydney University – sequence: 4 givenname: David O. surname: Irving fullname: Irving, David O. organization: University of Technology Sydney |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34936102$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU9PFDEYhxuDkQU8-AVMEy9wGOifmU7nuKwiJiQkC3idtDNvsaTbrm1Hsp6Mn8DP6CexsOjBRN9Dm7RPnv6a3x7a8cEDQq8oOaZlTnI0x1S0kj5DM9rwtmJd1-ygGSE1rSjlbBftpXRHCGEdoS_QLq87LihhM_R9rhP4AXAweAgxglPZBo815HsAj-enl3j56fDtEdYuhBHfxjCtsfIj9jDlqJz9av1tOchWh3GDs80QE7YeX82XVz-__ViEj2VlRe6_KAdpAJ_x2qm0UngMPsR0gJ4b5RK8fNr30c3Zu-vFeXVx-f7DYn5RDVxSWnHWSDKQmtVtU3e6_ETL1hA5CsKMrIUUMGpqNGgGpm10K4Zyp6UCbiQvs48Ot951DJ8nSLlf2RLHOeUhTKlngrKWN4KJgr75C70LU_QlXaEKRJho6v9TlJVckjw8e7SlhhhSimD6dbQrFTc9Jf1DfX2pr3-sr7Cvn4yTXsH4h_zdVwFOtsC9dbD5t6m_Xp5tlb8A1eyl9A |
CitedBy_id | crossref_primary_10_3389_fimmu_2023_1191479 crossref_primary_10_1080_23744235_2022_2115548 crossref_primary_10_3390_epidemiologia4010007 |
Cites_doi | 10.1016/j.antiviral.2020.104880 10.1001/jama.2020.10044 10.1111/bjh.16932 10.1111/vox.13076 10.1016/S0140-6736(21)00897-7 10.1111/bjh.16884 10.1371/journal.pmed.1003346 10.1007/s00277-020-04169-1 10.1111/vox.13070 10.1111/vox.13062 10.1186/1477-9560-5-14 10.1001/jama.2020.8598 10.3390/v13020247 10.1111/trf.15946 |
ContentType | Journal Article Web Resource |
Copyright | 2021 AABB. 2021. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com 2022 AABB |
Copyright_xml | – notice: 2021 AABB. – notice: 2021. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com – notice: 2022 AABB |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION COVID 7QO 7U9 8FD FR3 H94 K9. P64 7X8 |
DOI | 10.1111/trf.16781 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Coronavirus Research Database Biotechnology Research Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Coronavirus Research Database Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Virology and AIDS Abstracts MEDLINE Coronavirus Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: COVID name: Coronavirus Research Database url: https://proxy.k.utb.cz/login?url=https://search.proquest.com/coronavirus sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1537-2995 |
EndPage | 297 |
ExternalDocumentID | 10_1111_trf_16781 34936102 TRF16781 |
Genre | shortCommunication Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Australia |
GeographicLocations_xml | – name: Australia |
GrantInformation_xml | – fundername: Australian governments |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 123 1OB 1OC 29Q 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABLJU ABPVW ABQWH ABXGK ACAHQ ACBNA ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EGARE EJD EMOBN ESX EX3 F00 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ H~9 IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SJN SUPJJ TEORI TWZ UB1 UCJ V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQJ WUP WVDHM WXI WXSBR X7M XG1 YFH YQI YQJ YUY ZGI ZXP ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAMNL AAYXX ACYXJ CITATION COVID 7QO 7U9 8FD FR3 H94 K9. P64 7X8 |
ID | FETCH-LOGICAL-c3811-32580c04247549b290b87f08d602f84686edb1fbeb2ef75b76c8d6b8ae3f83333 |
IEDL.DBID | DR2 |
ISSN | 0041-1132 |
IngestDate | Wed Dec 04 14:48:27 EST 2024 Fri Nov 22 18:34:08 EST 2024 Thu Oct 10 16:37:15 EDT 2024 Fri Dec 06 02:47:26 EST 2024 Sat Sep 28 08:21:29 EDT 2024 Sat Aug 24 00:57:33 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | blood group SARS-CoV-2 convalescent plasma |
Language | English |
License | 2021 AABB. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3811-32580c04247549b290b87f08d602f84686edb1fbeb2ef75b76c8d6b8ae3f83333 |
Notes | Funding information Australian governments fund Australian Red Cross Lifeblood to provide blood, blood products, and services to the Australian community. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-0371-9515 0000-0002-7827-3661 |
PMID | 34936102 |
PQID | 2612602803 |
PQPubID | 4686273 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_2612735626 proquest_journals_2627302654 proquest_journals_2612602803 crossref_primary_10_1111_trf_16781 pubmed_primary_34936102 wiley_primary_10_1111_trf_16781_TRF16781 |
PublicationCentury | 2000 |
PublicationDate | February 2022 |
PublicationDateYYYYMMDD | 2022-02-01 |
PublicationDate_xml | – month: 02 year: 2022 text: February 2022 |
PublicationDecade | 2020 |
PublicationPlace | Hoboken, USA |
PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Hoboken – name: Bethesda |
PublicationTitle | Transfusion |
PublicationTitleAlternate | Transfusion |
PublicationYear | 2022 |
Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
References | 2021; 13 2020; 190 2021 2020; 60 2021; 116 2020; 181 2021; 19 2020; 17 2020; 324 2007; 5 2020; 323 2020; 99 2021; 397 2020; 509 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 Franchini M (e_1_2_7_10_1) 2021; 19 e_1_2_7_11_1 e_1_2_7_22_1 e_1_2_7_21_1 e_1_2_7_20_1 Zhao J (e_1_2_7_7_1) 2020; 509 |
References_xml | – volume: 60 start-page: 1883 year: 2020 end-page: 4 article-title: COVID‐19 and ABO blood groups publication-title: Transfusion – volume: 17 year: 2020 article-title: Occurrence and transmission potential of asymptomatic and presymptomatic SARS‐CoV‐2 infections: a living systematic review and meta‐analysis publication-title: PLoS Med – volume: 116 start-page: 471 year: 2021 end-page: 2 article-title: Subjects with blood group O are not at lower risk to acquire SARS‐CoV‐2 infection publication-title: Vox Sang – volume: 190 year: 2020 article-title: COVID‐19 and ABO blood group: another viewpoint publication-title: Br J Haematol – volume: 181 year: 2020 article-title: Lower prevalence of antibodies neutralizing SARS‐CoV‐2 in group O French blood donors publication-title: Antiviral Res – volume: 116 start-page: 766 year: 2021 end-page: 73 article-title: ABO blood group and SARS‐CoV‐2 antibody response in a convalescent donor population publication-title: Vox Sang – volume: 190 start-page: e148 year: 2020 end-page: e50 article-title: Anti‐A isohaemagglutinin titres and SARS‐CoV‐2 neutralization: implications for children and convalescent plasma selection publication-title: Br J Haematol – volume: 5 start-page: 14 year: 2007 article-title: Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications publication-title: Thromb J – volume: 324 start-page: 460 year: 2020 end-page: 70 article-title: Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life‐threatening COVID‐19: a randomized clinical trial publication-title: JAMA – year: 2021 – volume: 99 start-page: 2113 year: 2020 end-page: 8 article-title: Blood type and outcomes in patients with COVID‐19 publication-title: Ann Hematol – volume: 19 start-page: 317 year: 2021 end-page: 26 article-title: ABO blood group and COVID‐19: an updated systematic literature review and meta‐analysis publication-title: Blood Transfus – volume: 323 start-page: 2466 year: 2020 end-page: 7 article-title: COVID‐19 and racial/ethnic disparities publication-title: JAMA – volume: 509 start-page: 220 year: 2020 end-page: 3 article-title: Relationship between the ABO blood group and the coronavirus disease 2019 (COVID‐19) susceptibility publication-title: Clin Infect Dis – volume: 13 start-page: 247 year: 2021 article-title: SARS coronavirus‐2 microneutralisation and commercial serological assays correlated closely for some but not all enzyme immunoassays publication-title: Viruses – volume: 116 start-page: 849 year: 2021 end-page: 61 article-title: ABO blood group and COVID‐19: a review on behalf of the ISBT COVID‐19 working group publication-title: Vox Sang – volume: 397 start-page: 2049 year: 2021 end-page: 59 article-title: Convalescent plasma in patients admitted to hospital with COVID‐19 (RECOVERY): a randomised controlled, open‐label, platform trial publication-title: Lancet – ident: e_1_2_7_16_1 doi: 10.1016/j.antiviral.2020.104880 – ident: e_1_2_7_5_1 – ident: e_1_2_7_14_1 doi: 10.1001/jama.2020.10044 – ident: e_1_2_7_20_1 doi: 10.1111/bjh.16932 – ident: e_1_2_7_11_1 doi: 10.1111/vox.13076 – ident: e_1_2_7_2_1 – volume: 509 start-page: 220 year: 2020 ident: e_1_2_7_7_1 article-title: Relationship between the ABO blood group and the coronavirus disease 2019 (COVID‐19) susceptibility publication-title: Clin Infect Dis contributor: fullname: Zhao J – ident: e_1_2_7_13_1 doi: 10.1016/S0140-6736(21)00897-7 – ident: e_1_2_7_22_1 doi: 10.1111/bjh.16884 – ident: e_1_2_7_3_1 – ident: e_1_2_7_12_1 doi: 10.1371/journal.pmed.1003346 – ident: e_1_2_7_8_1 doi: 10.1007/s00277-020-04169-1 – ident: e_1_2_7_15_1 doi: 10.1111/vox.13070 – ident: e_1_2_7_17_1 – ident: e_1_2_7_19_1 doi: 10.1111/vox.13062 – ident: e_1_2_7_4_1 – ident: e_1_2_7_21_1 doi: 10.1186/1477-9560-5-14 – ident: e_1_2_7_6_1 doi: 10.1001/jama.2020.8598 – ident: e_1_2_7_18_1 doi: 10.3390/v13020247 – ident: e_1_2_7_9_1 doi: 10.1111/trf.15946 – volume: 19 start-page: 317 year: 2021 ident: e_1_2_7_10_1 article-title: ABO blood group and COVID‐19: an updated systematic literature review and meta‐analysis publication-title: Blood Transfus contributor: fullname: Franchini M |
SSID | ssj0002901 |
Score | 2.4215763 |
Snippet | Background
Several studies have described associations between ABO blood group and SARS‐CoV‐2 infection severity in hospitalized patients where group A... Several studies have described associations between ABO blood group and SARS-CoV-2 infection severity in hospitalized patients where group A individuals are... Background Several studies have described associations between ABO blood group and SARS-CoV-2 infection severity in hospitalized patients where group A... BackgroundSeveral studies have described associations between ABO blood group and SARS‐CoV‐2 infection severity in hospitalized patients where group A... BACKGROUNDSeveral studies have described associations between ABO blood group and SARS-CoV-2 infection severity in hospitalized patients where group A... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 292 |
SubjectTerms | ABO Blood-Group System ABO system Animals Antibodies Antibodies, Neutralizing - blood Antibodies, Viral - blood Australia Blood & organ donations Blood Donors blood group Blood groups Chlorocebus aethiops convalescent plasma COVID-19 - therapy Demography Humans Immunization, Passive Infections Neutralization Tests Neutralizing Plasmapheresis SARS-CoV-2 - immunology SARS‐CoV‐2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Vero Cells |
SummonAdditionalLinks | – databaseName: Coronavirus Research Database dbid: COVID link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagvSAOUPEKlGpAHMrByyZ2HO8JbbesChJU2j7oLbJjW60QybLJHuiB387YcVoVVA7kFNlSNLHHns8zn2cIeSNQcbmSjuaiqLzrZkw1tlGXKZFJzRTn_r7z5y_i4IR_OsvPosOtjbTKYU8MG7VpKu8jf-dTXQkfB2Tvlz-orxrlo6uxhMZdsskQOqCGb84OTz_uxxRCnrLTrdwoxR05vWl4_kKTN8FpsC7zB6Qc5OpJJd9G606Pqss_Ujb-v-APyf2vVsPgqt8id2z9iPya6tava2gcVL5IR0-Lg0jdguneISzOd_ffQmC3Q7gAAqo2UNt1cJBcot3Dhu5CN-YnhAzNLVzUcDRdHNFZc0oz8Kx2FXNGwRKh-ncFpqmbVfuYnMw_HM8OaCzHQCs06yllWS7HlQ-VFnio1NlkrGXhxtLg3zmEMVJYo1On8axuXZHrQlTYp6WyzEmGzxOyUTe1fUbAcZsxbXgheIoITk0Ms0YaWelCaWknCXk9zFW57LNulMNpBSe0DBOakO1hwMu48NryerRv6Ua4hsfOnCfk1VU3rigfJlG1bdb9JwqGuFAk5GmvHFdCMD5hCDizhOwGbblduvJ4MQ8vz_8t5gtyL_M3KgIRfJtsdKu1fYk4p9M7UZl_A2JLAAE priority: 102 providerName: ProQuest |
Title | Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS‐CoV‐2 convalescent plasma donors |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ftrf.16781 https://www.ncbi.nlm.nih.gov/pubmed/34936102 https://www.proquest.com/docview/2612602803 https://www.proquest.com/docview/2627302654 https://search.proquest.com/docview/2612735626 |
Volume | 62 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB5VRUJcKP-klMogDuWQ1SZ2bK84LbusClKptP1RD0iRHduiqppUm-yBnhBPwDP2STp2koWCKiFyiCI7iRzbk_nG880Y4A3HicuUdHHGReGXboaxxrLYpYqnUlPFmI933vvMd4_Yp5PsZA3e9bEwbX6I1YKbl4zwv_YCrnT9m5A3CzdI8FfrTZ-ECk_nm85_pY7y_sHWu5zEfjf1LquQZ_Gsnrypi_4CmDfxalA4sw340je15ZmcDZaNHhSXf2Rx_M9veQD3OyBKxu3MeQhrtnwEd_c6V_tj-DHWtZd6UjlS-C08WtIc6YhdZPx-n8y_7kzfksB9JyE8hKjSkNIuw_LJJWpFLGhOdWW-kZC_uSanJTkYzw-uvv-cVMd4TonnvasuqxS5QDB_roipympRP4Gj2YfDyW7cbdgQF6j4k5immRwW3pkq0OzUOARaCjeUhg9Th0BHcmt04jRa89aJTAteYJ2WylInKR5PYb2sSvsciGM2pdowwVmCGE-NDLVGGlloobS0owhe90OXX7R5OfLensHezENvRrDVD2reiWad-5xp3DuU6S3VCOjQMM1YBK9W1Shz3pGiSlst21cIisiRR_CsnSurRlA2oghJ0wh2wojf3rr8cD4LF5v_fusLuJf6-ItAG9-C9WaxtC8RFTV6G-5M9o8_TreDGFwDz6kKVQ |
link.rule.ids | 314,780,784,1375,27924,27925,38516,43895,46294,46718 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7B9gDiUBCvlAIGcSgHbzdx4nhPaNmy2kIf0nZbeovs2BYVarJssof20N_esZMUFVQO5BTZUjSxx57PM59nAD5wVNxYCksTnubOdTOgCtuojSSPhGIyjt195_0DPj2Ov54mp63DrWppld2e6DdqXebOR77tUl1xFwdknxa_qKsa5aKrbQmN-7DmqngnPVgbH57s7rQphBxlp17afog7cnjb8PyFJm-DU29dJuuQdXI1pJKf_VWt-vnlHykb_1_wx_Dou1Gkc9U_gXumeApXI1W5dU1KS3JXpKOhxZGWukVGnw_J7MfWzkfi2e3EXwAhstCkMCvvILlEu4cN9Zkq9QXxGZorclaQo9HsiI7LExoRx2qXbc4oskCofi6JLotyWT2D48mX-XhK23IMNEezHlIWJWKQu1BpiodKFQ0HSqR2IDT-nUUYI7jRKrQKz-rGpolKeY59SkjDrGD4PIdeURbmJRAbm4gpHac8DhHByaFmRgstcpVKJcwwgPfdXGWLJutG1p1WcEIzP6EBbHYDnrULr8p-j_Yd3QjX8NiZxAG8u-nGFeXCJLIw5ar5RMoQF_IAXjTKcSMEi4cMAWcUwJbXlruly-aziX_Z-LeYb-HBdL6_l-3tHnx7BQ8jd7vCk8I3oVcvV-Y1Yp5avWkV-xqTXALx |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB5VrVRxgfKftoBBHMohq43tOF5xWrqsyk8L2raoh0qRHduiQk1Wu9lDe0I8Ac_IkzB2koWCKiFyiCI7iRzbk_nGM_MZ4LnAicuVdHEqssIv3fRjjWWxo0pQqZni3Oc77x-IvWP-9iQ9WYGXXS5Mww-xXHDzkhH-117Ap8b9JuT1zPUS_NWi6bPGBR144vzR5Bd3lHcQNu7lJPbbqbe0Qj6MZ_noVWX0F8K8CliDxhnfgtOurU2gyZfeota94vIPGsf__JgNuNkiUTJsps5tWLHlHVjfb33td-HbUM-92JPKkcLv4dFEzZE2sosMX30gk887oxckBL-TkB9CVGlIaRdh_eQS1SIW1Ge6MhckEDjPyVlJDoeTwx9fv-9Wn_BMiQ98Vy2tFJkimj9XxFRlNZvfg-Px66PdvbjdsSEuUPMnMaOp7Bfem5qh3alxCLTMXF8a0acOkY4U1ujEaTTnrctSnYkC67RUljnJ8LgPq2VV2odAHLeUacMzwRMEeWpgmDXSyEJnSks7iOBZN3T5tCHmyDuDBnszD70ZwXY3qHkrm_Pck6YJ71Fm11QjokPLNOURPF1Wo9B5T4oqbbVoXpExhI4iggfNXFk2gvEBQ0xKI9gJI3596_KjyThcbP77rU9g_eNonL9_c_BuC25Qn4sRQsi3YbWeLewjREi1fhwk4SfkvQuN |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Absence+of+correlation+between+ABO+Rh%28D%29+blood+group+and+neutralizing+antibody+titers+in+SARS%E2%80%90CoV%E2%80%902+convalescent+plasma+donors&rft.jtitle=Transfusion+%28Philadelphia%2C+Pa.%29&rft.au=Hirani%2C+Rena&rft.au=Hoad%2C+Veronica&rft.au=Gosbell%2C+Iain+B&rft.au=Irving%2C+David+O&rft.date=2022-02-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0041-1132&rft.eissn=1537-2995&rft.volume=62&rft.issue=2&rft.spage=292&rft.epage=297&rft_id=info:doi/10.1111%2Ftrf.16781&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-1132&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-1132&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-1132&client=summon |